Novavax (NVAX -0.98%) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's investigational vaccine -- then plummeted 98% from their peak as the vaccine entered the market late, missing out on the biggest revenue opportunity.Today, the company is generating sales from its vaccine, but less than anticipated, and that's forced Novavax to realign its cost base with the revenue opportunity. The biotech l ...

A few years ago, biotech company Novavax (NVAX -0.98%) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.However, there have been a lot of negative developments for Novavax since then, and as a result, the biotech has given up all of its gains. Is there any hope for Novavax? If the company can improve its situation, investors who get in on the stock now could earn outsized returns.Let's find out whether Novavax is like ...

There was a lot of promise around Novavax (NVAX -0.98%) and its COVID vaccine a few years ago. But with the company being late to the finish line and now generating limited revenue from the vaccine, it has effectively missed the boat and the huge revenue that rivals Moderna and Pfizer have accumulated.Novavax's future remains uncertain these days, as the company is back to needing a strong product to build its business around. Here's a look at where Novavax might be five years from now, and whether it's wor ...

Novavax (NVAX 3.21%) soared more than 2,700% early in the pandemic as investors bet on its ability to bring a coronavirus vaccine to market. The company followed through on that -- but not as quickly as planned. Novavax's product launched more than a year after those of rivals. This meant Novavax missed out on the biggest revenue opportunity, disappointing investors. As a result, the stock plummeted, and today is down 98% from its peak.The vaccine maker has gone through difficult times, having to lower cost ...

Novavax, Inc. (NASDAQ:NVAX) JPMorgan 42nd Annual Healthcare Conference January 8, 2024 8:15 PM ET Company Participants John Jacobs - President and CEO John Trizzino - Chief Commercial Officer & Chief Business Officer James Kelly - CFO Filip Dubovsky - President of Research & Development Conference Call Participants Eric Joseph - JPMorgan Eric Joseph All right, okay. We'll get started here. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. And our next presenting company is Novavax. Presenting on behalf ...

Novavax, Inc. (NASDAQ: NVAX) Conference Call Summary Company Overview - **Company**: Novavax, Inc. - **Industry**: Biotechnology, specifically vaccine development - **Key Participants**: - John Jacobs - President and CEO - John Trizzino - Chief Commercial Officer & Chief Business Officer - James Kelly - CFO - Filip Dubovsky - President of Research & Development Core Points and Arguments 1. **Vaccination Impact**: Novavax emphasizes the importance of vaccination in preventing diseases such as malaria, flu, and COVID-19, highlighting that millions of lives can be saved through vaccination efforts [6][7][8] 2. **Product Portfolio**: The company has launched its COVID-19 vaccine, including an updated version for the XBB.1.5 strain, and is advancing a combination Flu/COVID vaccine expected to launch in 2026 [7][8][9] 3. **Technology Platform**: Novavax utilizes a unique protein-based technology and Matrix-M adjuvant, which enhances immune response and allows for the development of combination vaccines [8][9][10] 4. **Global Partnerships**: The company has established strategic partnerships with organizations like SK Bio, Takeda, and Serum Institute of India to enhance manufacturing and distribution capabilities [8][9] 5. **Market Positioning**: Novavax aims to improve product presentation and awareness in the U.S. market, transitioning from emergency use authorization to a full marketing license in 2024 [17][18][19] 6. **Financial Restructuring**: In 2023, Novavax reduced its workforce by 20%, cut $1 billion in current liabilities, and aims for a 55% reduction in operating expenses by 2024 [13][14][26] 7. **Revenue Outlook**: The company anticipates approximately $2 billion in revenue from committed contracts and cash reserves, positioning itself for future growth [38][39] 8. **Combination Vaccine Development**: Novavax is focused on advancing its combination vaccine program, with plans for a Phase 3 trial in the second half of 2024 and potential market entry in 2026 [25][58] Additional Important Content 1. **Awareness Campaigns**: The company has significantly increased awareness among healthcare providers from 46% to 80% in the past year, which is crucial for market penetration [20][30] 2. **Manufacturing Strategy**: Novavax is considering selling its Czech Republic manufacturing facility to streamline operations and reduce costs, while relying on partners for vaccine production [27][40][45] 3. **Matrix-M Adjuvant Opportunities**: The company is exploring additional uses for its Matrix-M adjuvant, including collaborations with the Bill and Melinda Gates Foundation and other global partners [47][48][49] 4. **Regulatory Pathways**: Novavax is preparing for discussions with the FDA regarding the approval process for its combination vaccine, aiming for an accelerated approval pathway [58] This summary encapsulates the key insights from the conference call, focusing on Novavax's strategic direction, product development, financial health, and market positioning within the biotechnology industry.

GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST) Location: Westin St. Francis Hotel in San Francisco, California Moderator: Eric Joseph, Ph.D., Executive Director ...

novavax: ...... Q3 2023 • Total revenue primarily driven by $165 million in grant revenue Q3 2022 | --- | --- | --- | --- | --- | |-------------------------------------------|-------|---------|-------|---------| | ($ in millions, except per share amounts) | | Q3 2023 | | Q3 2022 | | Product sales | $ | 2 | $ | 626 | | Grants | | 1 65 | | IOR | | Royalties and other | | 20 | | 2 | | Total revenue | | 187 | | 735 | | Cost of sales | | 99 | | 435 | | Research and development | | 106 | | 304 | | Selling, genera ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR (Address of principal executive offices) (Zip code) (240) 268-2000 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 00 ...

Financial Data and Key Metrics - Total revenue for Q2 2023 was $424 million, a 128% increase compared to $186 million in Q2 2022 [152] - Combined R&D and SG&A expenses for Q2 2023 were $313 million, a 21% decrease compared to Q2 2022 [137] - The company ended Q2 2023 with $518 million in cash and $395 million in accounts receivable, totaling over $900 million [153] - Net income for Q2 2023 was $58 million, compared to a net loss of $510 million in Q2 2022 [155] - The company reduced current liabilities by $864 million in the first half of 2023, including $323 million in Q2 2023 [141][182] Business Line Data and Key Metrics - The company's COVID vaccine is authorized in over 40 countries, with many still purchasing under Advanced Purchase Agreements (APAs) [21] - In the US, the company is preparing for commercialization, with product availability expected as early as September, pending FDA authorization [22][24] - Outside the US, the company expects approximately $700 million in revenue from APA orders for 2023, subject to regulatory approvals [31] - The company has amended its APA with Canada, securing up to $350 million in cash payments for 2023 and extending commitments into 2024 and 2025 [13][32] Market Data and Key Metrics - The US market demand for COVID vaccines in the fall is estimated to range between 80 million to 100 million doses [55] - In Europe, the company expects to deliver 17 million committed doses by the end of 2023, with strong relationships in key markets like Germany, Spain, France, Italy, and Switzerland [74] - In the Asia-Pacific region, the company continues to supply vaccines under existing APAs to Australia, New Zealand, Singapore, Taiwan, and Israel [75] Company Strategy and Industry Competition - The company's three priorities for 2023 are: delivering an updated vaccine for the fall season, reducing spending and managing cash flow, and driving value from its technology platform [9][12][15] - The company is focusing on developing a combination COVID-influenza vaccine, recognizing the emerging need for combination vaccines as COVID becomes a seasonal challenge [45] - The company's Matrix-M adjuvant is being used in collaborations, including a new partnership with the Bill & Melinda Gates Medical Research Institute for preclinical vaccine research [47][249] Management Commentary on Operating Environment and Future Outlook - The company is confident in its readiness to deliver an updated, differentiated, and competitive vaccine for the fall season, with ample supply to meet anticipated demand [39][40] - Management acknowledges significant execution risks, particularly in securing regulatory authorizations and competing in the US market as it transitions to a commercial model [48] - The company expects to achieve full-year 2023 revenue of between $1.3 billion and $1.5 billion, with product sales of $960 million to $1.140 billion and grant revenue of $340 million to $360 million [193] Other Important Information - The company has secured up to $600 million in cash to improve its cash runway, including $450 million from the amended Canada APA [160] - The company has reduced its outstanding liabilities by over $1 billion in 2023, including a $195 million reduction through agreements with SK Bioscience [157][182] - The company is on track to reduce combined R&D and SG&A expenses to between $1.3 billion and $1.4 billion for 2023, reflecting a 20% to 25% reduction compared to 2022 [158] Q&A Session Summary Question: What is the status of the BLA approval for the XBB vaccine? - The company has initiated the rolling submission of its BLA filing and expects to complete the submission in the coming weeks, with full approval anticipated in early 2024 [64][227] Question: What is the pricing strategy for the US market? - The company's pricing strategy is aligned with publicly stated WACC (Weighted Average Cost of Capital) of $130 per dose, with reimbursement calculations incorporated into the overall access strategy [220][238] Question: What are the key drivers for gaining market share in the US? - Key drivers include ensuring broad access to the vaccine across all market segments, competitive pricing, and the availability of a non-mRNA protein-based vaccine option [204][206] Question: What is the status of the Wuhan strain deliveries in the EU? - The company has completed shipments of the Wuhan strain in the EU and will be delivering the updated XBB variant strain for the fall season [226] Question: What is the timeline for removing the going concern disclosure? - The company is optimistic about its operating plan and expects to remove the going concern disclosure if it successfully executes its plans, particularly in the fall vaccine season [207]